These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Abciximab-induced delayed profound thrombocytopaenia.
    Author: Jbara M, Bhogal S, Bajaj K, Chhabra L.
    Journal: BMJ Case Rep; 2017 Jun 02; 2017():. PubMed ID: 28576909.
    Abstract:
    Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.
    [Abstract] [Full Text] [Related] [New Search]